Mechanism of Action
Membrane Disruption
Dermaseptins adopt an amphipathic alpha-helical conformation upon contact with bacterial membranes. The cationic face selectively interacts with anionic phospholipids in bacterial membranes, leading to carpet-model disruption, pore formation, and cell lysis. Eukaryotic membranes, which are enriched with zwitterionic phospholipids, show relative resistance at low concentrations.
Antiparasitic and Antifungal Activity
Dermaseptin S1 and S4 show potent activity against Plasmodium falciparum (IC50 ~1 uM), Leishmania species, and Candida albicans. The mechanism involves disruption of the unique lipid composition of these pathogens membranes. Studies have proposed dermaseptins as scaffolds for next-generation antiprotozoal agents.
Anticancer Mechanisms
Several dermaseptin analogs selectively lyse cancer cell lines including prostate, breast, and lung carcinomas. The preferential targeting is attributed to the overexpression of phosphatidylserine on the outer leaflet of cancer cell membranes, which mimics the bacterial membrane charge signature.
Research Summary
Antimalarial Research
PreclinicalDermaseptin S1 and B2 demonstrate sub-micromolar activity against chloroquine-resistant P. falciparum strains in vitro. Conjugation to targeting moieties has been explored to improve selectivity and reduce hemolytic activity, a key limitation for systemic antimalarial use.
Cancer Cell Selectivity
PreclinicalModified dermaseptins with reduced hemolytic toxicity show selective killing of prostate cancer cells at concentrations sparing normal epithelial cells. The SV6D variant and DRS-B2 analogs have been studied for tumor models. Full therapeutic development remains limited by stability and delivery challenges.
Calculate your Dermaseptin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial testing | 1-10 uM (in vitro) | Single exposure | Direct application |
| Anticancer cell line | 5-50 uM (in vitro) | Single treatment | Direct application |
No established human research protocols. All dosing is based on in vitro or animal studies.
Interactions
Safety Profile
Hemolytic activity at higher concentrations is the primary toxicity concern for systemic use. Topical applications show better tolerability. No human clinical data available. Stability in physiological fluids is limited due to rapid proteolytic degradation.
References
- [1]Zasloff M. (2002). Antimicrobial peptides of multicellular organisms. Nature, 415(6870), 389-395.
- [2]Mor A, et al. (1991). Isolation, amino acid sequence, and synthesis in living cells of dermaseptin b, a novel vertebrate defensive peptide. Biochemistry, 30(36), 8824-8830.
- [3]Rinia HA, et al. (2002). Structural insights into the mechanism of action of Dermaseptin DS1 on phospholipid bilayers. Biochemistry, 41(8), 2506-2513.